Quest Diagnostics Incorporated $DGX Shares Purchased by Blair William & Co. IL

Blair William & Co. IL raised its holdings in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 7.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 97,918 shares of the medical research company’s stock after acquiring an additional 6,709 shares during the period. Blair William & Co. IL owned approximately 0.09% of Quest Diagnostics worth $18,661,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Brighton Jones LLC acquired a new stake in Quest Diagnostics during the fourth quarter worth about $323,000. Atlantic Union Bankshares Corp acquired a new position in Quest Diagnostics in the second quarter valued at approximately $81,000. Resona Asset Management Co. Ltd. boosted its position in Quest Diagnostics by 4.3% in the 2nd quarter. Resona Asset Management Co. Ltd. now owns 45,601 shares of the medical research company’s stock worth $8,180,000 after purchasing an additional 1,861 shares in the last quarter. Savant Capital LLC grew its stake in shares of Quest Diagnostics by 1.1% during the 2nd quarter. Savant Capital LLC now owns 12,281 shares of the medical research company’s stock worth $2,206,000 after purchasing an additional 130 shares during the period. Finally, First Eagle Investment Management LLC grew its stake in shares of Quest Diagnostics by 2.7% during the 2nd quarter. First Eagle Investment Management LLC now owns 5,697 shares of the medical research company’s stock worth $1,023,000 after purchasing an additional 148 shares during the period. Institutional investors and hedge funds own 88.06% of the company’s stock.

Quest Diagnostics Trading Down 2.3%

Shares of NYSE DGX opened at $199.37 on Monday. The stock has a fifty day simple moving average of $191.66 and a 200-day simple moving average of $185.77. Quest Diagnostics Incorporated has a twelve month low of $157.20 and a twelve month high of $213.50. The company has a current ratio of 1.04, a quick ratio of 0.96 and a debt-to-equity ratio of 0.72. The stock has a market capitalization of $21.90 billion, a PE ratio of 22.79, a PEG ratio of 2.57 and a beta of 0.65.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Tuesday, February 10th. The medical research company reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.35 by $0.07. The company had revenue of $2.81 billion during the quarter, compared to analysts’ expectations of $2.75 billion. Quest Diagnostics had a return on equity of 15.57% and a net margin of 8.99%.Quest Diagnostics’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same period last year, the business posted $2.23 EPS. Quest Diagnostics has set its FY 2026 guidance at 9.45-9.650 EPS. On average, equities analysts forecast that Quest Diagnostics Incorporated will post 9.7 earnings per share for the current year.

Quest Diagnostics Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 20th. Investors of record on Monday, April 6th will be issued a $0.86 dividend. This represents a $3.44 dividend on an annualized basis and a dividend yield of 1.7%. This is an increase from Quest Diagnostics’s previous quarterly dividend of $0.80. The ex-dividend date is Monday, April 6th. Quest Diagnostics’s dividend payout ratio (DPR) is presently 36.57%.

Quest Diagnostics announced that its board has initiated a share repurchase plan on Tuesday, February 10th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy up to 4.7% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its shares are undervalued.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on DGX. Mizuho boosted their target price on shares of Quest Diagnostics from $210.00 to $235.00 and gave the company an “outperform” rating in a research note on Thursday, February 12th. Barclays increased their target price on Quest Diagnostics from $210.00 to $225.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Robert W. Baird set a $219.00 price target on shares of Quest Diagnostics in a research note on Wednesday, February 11th. Citigroup lifted their price objective on Quest Diagnostics from $190.00 to $215.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 10th. Finally, Truist Financial lifted their target price on shares of Quest Diagnostics from $205.00 to $220.00 and gave the stock a “hold” rating in a research note on Wednesday, February 11th. Eight investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $210.29.

Quest Diagnostics News Roundup

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Zacks Research expects higher Q4/near-term earnings for Quest, which supports the company’s fundamentals and could be a near-term tailwind if results and guidance confirm those estimates. Zacks Research Expects Higher Earnings for Quest Diagnostics
• Neutral Sentiment: Equity analysts have set/updated expectations for DGX Q4 earnings (consensus estimates being monitored ahead of the print); this keeps focus on results and guide as the primary near-term catalysts. Equities Analysts Set Expectations for DGX Q4 Earnings
• Neutral Sentiment: Options traders are driving implied volatility higher on DGX, indicating the market is pricing a larger-than-normal move around upcoming news (increases trading costs and can amplify share moves in either direction). Implied Volatility Surging for Quest Diagnostics Stock Options
• Negative Sentiment: Multiple senior executives completed sizable stock sales this week (SVPs and an EVP sold shares at ~ $204–$206 each). Combined disclosed sales total roughly $3.07M and represented single-digit to mid-teens percentage reductions in holdings — a negative signal that likely pressured the stock given concentration of selling among insiders. SEC Filing (Form 4) — Karthik Kuppusamy

Insider Buying and Selling at Quest Diagnostics

In other Quest Diagnostics news, EVP Catherine T. Doherty sold 5,558 shares of the business’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $206.21, for a total value of $1,146,115.18. Following the completion of the transaction, the executive vice president owned 67,122 shares in the company, valued at $13,841,227.62. The trade was a 7.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Patrick Plewman sold 2,855 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $206.21, for a total value of $588,729.55. Following the sale, the senior vice president directly owned 15,198 shares in the company, valued at $3,133,979.58. This represents a 15.81% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 24,083 shares of company stock valued at $4,945,262 in the last 90 days. Corporate insiders own 8.16% of the company’s stock.

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.